Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1637-1641

  Stephens, A W ^a   Gonin, R ^a   Hutchins, G D ^a   Einhorn, L H ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TERATOMA; THORACOTOMY; TUMOR NECROSIS;

EID: 0029923407     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1637     Document Type: Article

References (27)

1. Wozniak AJ, Samson MK, Shah NT, et al: A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: A Southwest Oncology Group study. J Clin Oncol 9:70-76, 1991
2. Ozols RF, Ihde DC, Linehan WM, et al: A randomized trial of standard chemotherapy versus a high-dose chemotherapy regimen in the treatment of poor prognosis germ cell tumors. J Clin Oncol 6:1031-1040, 1988
3. Levi JA, Thomson D, Sandeman T, et al: A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: Role of maintenance and long-term follow-up. J Clin Oncol 6:1154-1160, 1988
4. Williams SD, Birch B, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
5. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
6. Donohue JP, Rowland RG: The role of surgery in advanced testicular cancer. Cancer 54:2716-2721, 1984
7. Hendry WF, Barrett A, McElwain TJ, et al: The role of surgery in the combined management of metastases from malignant teratoma of testis. Br J Urol 52:38-44, 1980
8. Carter GE, Lieskovsky G, Skinner DG, et al: Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors. J Urol 138:1397-1401, 1987
9. Donohue JP, Rowland RG, Kopecky K, et al: Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137:1176-1179, 1987
10. Gelderman WA, Schraffordt, Koops H, et al: Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol 38:227-232, 1988
11. Stomper PC, Jochelson MS, Garnick MB, et al: Residual abdominal masses after chemotherapy for nonseminamatous testicular cancer: Correlation of CT and histology. Am J Radiol 145:743-746, 1985
12. Debono D and Einhorn LH. Decision analysis for post-chemotherapy in patients with disseminated non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 14:240, 1995 (abstr)
13. Toner GC, Panicek DM, Heelan RT, et al: Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection. J Clin Oncol 8:1683-1694, 1990
14. Fossa SD, Aass N, Ous S, et al: Histology of tumor residuals following chemotherapy in patients with advanced non-seminatomatous testicular cancer. J Urol 142:1239-1242, 1989
15. Warburg O: The Metabolism of Tumors. New York, NY, Smith, 1931, pp 129-169
16. Bergstrom M: Positron emission tomography in tumor diagnosis and treatment follow-up. Acta Oncol 32:183-188, 1993
17. Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 32:623-648, 1991
18. Clark LA, Pregibon D: Tree based models, in Chambers JM, Hastie TJ (eds): Statistical Models in S. Pacific Grove, CA, Wadsworth Brooks, 1992, pp 377-419
19. Zar JH: Biostatistical Analysis (ed 2). Englewood Cliffs, NJ, Prentice-Hall, 1984, pp 390-395
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36, 1982
21. Donohue J, Rowland R: Complications of retroperitoneal lymph node dissection. J Urol 125:338-340, 1981
22. Donohue J, Foster R, Rowland R, et al: Nerve sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144:287-292, 1990
23. Doerr A, Skinner E, Skinner D, et al: Preservation of ejaculation through a modified retroperitoneal lymph node dissection in low stage testis cancer. J Urol 149:1472-1474, 1993
24. Motzer R, Bosl G, Morse M, et al: Residual mass: An indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 5:1064-1070, 1987
25. Schultz S, Einhorn LH, Loehrer P, et al: Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7:1497-1503, 1989
26. Warren G, Roth B, Einhorn LH: Gallium scans in the evaluation of residual masses after chemotherapy in seminoma. Proc Am Soc Clin Oncol 14:240, 1995 (abstr)
27. Baniel J, Foster R, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995